Pfizer (PFE) is focusing on earlier stage science for deals

Pfizer's pivot towards earlier stage science signals a strategic shift that could enhance its pipeline and innovation potential.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

CRUDE WRAP: WTI (N6) SETTLES USD 3.44 LOWER AT 98.07/BBL; BRENT (N6) SETTLES USD 4.57 LOWER AT 109.87/BBL

Assurant (AIZ) Q1 2026 (USD): Adj. EPS 5.95 (exp. 5.29), Adj. EBITDA 441.5mln (exp. 423.1mln); raises FY outlook

Pfizer (PFE) is focusing on earlier stage science for deals

US Senator Coons writes letter to Commerce Secretary Lutnick on Nvidia (NVDA) H200 chip exports

Pfizer (PFE) CEO announces review of novel molecule designed using AI

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This move may indicate confidence in future growth areas and could lead to value-accretive partnerships, potentially impacting sentiment in both the biotech sector and broader market. Investors will want to assess the implications for Pfizer's long-term strategy and how it positions them against competitors in pharmaceuticals.

Related headlines

The whole workspace, free to try.

Try it free